PGE2 Levels in Patient Treated With NSAIDs

• Status: Completed
• Trial end date: 2018-07-09
• Target enrollment: 0
• Participant gender: All

Summary

The aim of this study is to determine vitreous levels of nonsteroidal antinflammatory drugs (NSAIDs) and prostaglandinE2 (PGE2) in eyes scheduled for vitrectomy.

All patients received the study drugs for 3 days before surgery. 0.5 to 1.0 mL of undiluted vitreous was removed using the vitreous cutter positioned in the midvitreous cavity. Samples were immediately frozen and stored at -80°C until analysis.

Sample analyses were performed using an high-performance liquid chromatography system. The lower limit of quantitation was 0.8 ng/mL.

PGE2 levels were analyzed using the Prostaglandin E2 Monoclonal EIA Kit (Cayman Chemical Company) according to the manufacturer's instructions.

• Phase: Phase 3
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: University of Trieste
• Treatments: Bromfenac; Diclofenac; Indomethacin; Nepafenac; Ophthalmic Solutions

Criteria

Inclusion Criteria:

• epiretinal membrane or full thickness macular hole scheduled for vitrectomy

Exclusion Criteria:

• vitreous hemorrhage

• diabetes

• glaucoma

• concurrent retinovascular disease

• previous ocular inflammation

• previous ocular surgery

• history of ocular trauma

• previuos intravitreal injections

• concomitant intake of topical or systemic NSAIDs or corticosteroid therapy